In this Q&A, Anum Saeed, MD discusses how cardiologists must think beyond LDL and blood pressure, leveraging GLP-1 receptor agonists, SGLT-2 inhibitors, and emerging therapies to reduce cardiovascular...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
Nour Lyon, PA-C, outlines practical strategies from her AAPA Conference presentation to help clinicians identify high-risk patients, implement evidence-based prehabilitation, and reduce day-of-surgery...
In this interview, Ana Ormaza Vera, MD, discusses findings from a study she presented at the American College of Cardiology’s 74th Annual Scientific Session & Expo on March 29, 2025, in Chicago. She...
Steven E. Nissen, MD, lead author of the study “Bempedoic Acid And Cardiovascular Outcomes In Statin-Intolerant Patients,” answers questions on the importance of his team’s research on bempedoic acid, how...
In this interview, Emile d’Angremont, MSc, discusses the results of a recent study examining the use of cholinesterase inhibitors for the management of psychotic symptoms among patients with...
In this Q&A, Jordana B. Cohen, MD, MSCE, assistant professor of medicine and epidemiology at the University of Pennsylvania School of Medicine, and a nephrologist and research scientist at the...
Passive smoking exposure is known to cause adverse health outcomes, but what is the association between passive smoking exposure and the risk of hypertension? In this Q&A, Onoja Apka, PhD, answered...
How do patterns of blood pressure change over the life course and differ between men and women? A new analysis contradicts what you think you know. Lead researcher Susan Cheng, MD, MPH, MMSc, offers her...
Luke Joseph Laffin, MD, from the Cleveland Clinic Foundation, answers our questions about his research on the effect of phase 2 cardiac rehabilitation on exercise capacity and outcomes in patients with...
